About Us

Learn about who we are, what we believe
and the people who lead us

Our Story Serving patient needs is our passion; delivering revolutionary treatments is our mission Our Leadership Our experienced leaders are bound by passion and science Our Values We live our values of commitment, empowerment and teamwork Our Responsibility Advancing a vision for change Medical Affairs We are committed to advancing science and medicine through awareness, education and research

Our Focus

Discover our unique scientific approach
for diseases with high unmet need.

Demodex Blepharitis Highly prevalent and damaging eyelid disease Lyme Disease A growing public health crisis with no approved solution Rosacea A common inflammatory skin condition

Our Therapies

The first and only FDA-approved
treatment for Demodex blepharitis

XDEMVY® (lotilaner ophthalmic solution) 0.25% Available to prescribe today

Our Pipeline

Explore the possibilities of our robust pipeline
to address significant unmet patient needs

Pipeline Overview A commitment to pursuing the root cause of disease TP-04 An investigational treatment for papulopustular rosacea TP-05 An investigational therapy for the prevention of Lyme disease

Investors & News

Find additional corporate
and stock information.

Investors Overview

News & Presentations

Publications Corporate Governance

Stock Information

Other Resources

Our Story Our Leadership Our Values Our Responsibility Medical Affairs

Demodex Blepharitis Lyme Disease Rosacea

XDEMVY® (lotilaner ophthalmic solution) 0.25%

Pipeline Overview TP-04 TP-05

Careers

Financials

SEC Filings

Filing date	Form	Description	View
Sep 25, 2020	CORRESP	CORRESP	0001193125-20-254774.pdf 0001193125-20-254774.rtf 0001193125-20-254774.xls View HTML
Sep 24, 2020	UPLOAD	UPLOAD	0000000000-20-009026.pdf 0000000000-20-009026.rtf View HTML
Sep 14, 2020	DRS/A	mendment to a previously filed DRS	0000950123-20-009708.pdf 0000950123-20-009708.rtf 0000950123-20-009708.xls View HTML
Sep 4, 2020	UPLOAD	UPLOAD	0000000000-20-008365.pdf 0000000000-20-008365.rtf View HTML
Aug 14, 2020	DRS/A	mendment to a previously filed DRS	0000950123-20-009139.pdf 0000950123-20-009139.rtf 0000950123-20-009139.xls View HTML
Aug 7, 2020	DRS	Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy	0000950123-20-007975.pdf 0000950123-20-007975.rtf 0000950123-20-007975.xls View HTML

Anchor Link for Quarterly Results

Data provided by Kaleidoscope.